Online inquiry

IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10905MR)

This product GTTS-WQ10905MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL1A gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC), Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000575.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3552
UniProt ID P01583
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ10905MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6282MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ9620MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ8183MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ11039MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ6726MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ12419MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ10889MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ11984MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW